In the context of its research on infectious diseases and cancer, the IPBS regularly welcomes medical residents who are completing their Master 2 within the framework of a "Research Year". Future urological surgeon, Cécile Manceau, completed her Master 2 in Surgical Sciences (Paris XI) in the "Microenvironment, Cancer and Adipocytes" team led by Prof. Catherine Muller-Staumont under the supervision of Delphine Milhas and David Esteve.
In collaboration with the Department of Urology of the University Hospital, her work has shown that human periprostatic adipose tissue presents a specific tissue and vascular organization leading to a state of chronic hypoxia compared to other adipose deposits. This state of hypoxia creates an inflammatory and fibrotic environment in this tissue that favors the progression of prostate cancer in the vicinity.
The "Chirurgiens de l'Avenir" prize rewards young surgeons for their research activity and is awarded, in collaboration with the National Academy of Surgery, by the Fondation de l'Avenir*.
*The Fondation de l'Avenir's mission is to support and promote health research and innovation. Created in 1987 and supported by the Mutualité, it has been recognized as a public utility since 1988. Thanks to its vocation of general interest and its membership in the social economy, the Foundation embodies the link between the mutualist movement and the actors of public health. Through its actions, recommendations and publications, the Foundation actively participates in the improvement of our health care system.
The Fondation de l'Avenir is an essential lever in applied medical research. It enables researchers to advance their research projects and go beyond the fundamental stage, for the benefit of all. It provides growing funding for innovative approaches to support and care for patients and their families. Today, it can count on more than 64,000 donors, all of whom are mobilized to advance medical progress. Their generosity is essential to prepare the future of medicine.
The Foundation relies solely on private funding. It does not benefit from any public aid or subsidies.